Table 1.

Frequency of overall and selected vaccine adverse events (Comirnaty^a) and adverse reactions (CoronaVac^b and Vaxzevria^c) as reported in published COVID-19 vaccine clinical trials

Adverse event/reaction	Vaccine	18–59/16–55/18–55 years of age		≥ 60/56 years of age
		Intervention (%)	Control (%)	Intervention (%)	Control (%)
Injection-site pain	CoronaVac	8	7	7	3
	Comirnaty	83	14	71	9
	Vaxzevria	61	NR	29	NR
Fatigue	CoronaVac	7	2	3	0
	Comirnaty	47	33	34	23
	Vaxzevria	76	NR	44	NR
Fever	CoronaVac	3	2	2	1
	Comirnaty	4	1	1	0
	Vaxzevria	24	NR	0	NR
Headache	CoronaVac	2	0	0	0
	Comirnaty	42	34	25	18
	Vaxzevria	65	NR	44	NR
Overall (any adverse event)	CoronaVac	17	15	15	15
	Comirnaty	27	12	NR	NR
	Vaxzevria	98	74	85	48

NR not reported

^aOutcomes are for the two-dose regimen of Comirnaty 30 μg given 21 days apart. Adverse events within 7 days of the first dose were extracted from Figure 2 of Polack et al. [4]. The overall frequency of any adverse event was only reported for the overall safety population and not stratified by age group

^bOutcomes are for the two-dose regimen of CoronaVac 3 μg given 28 days apart (low dose). Adverse reactions were extracted from supplementary table 3–12 for the combined phase I/II trials (Zhang et al.) [2] and from supplementary table 3-3 for the phase II trial (Wu et al.) [1] reported within 28 days of the first dose

^cOutcomes are for the two-dose regimen of Vaxzevria (standard dose: 3.5–6.5 × 10¹⁰ virus particles) given 28 days apart. Adverse reactions were solicited up to 7 days after the first dose. Specific adverse reactions were extracted from supplementary table S5–S7, while overall adverse events indicate any local or systemic adverse reaction for the priming dose (supplementary table S12) [3]. Results for the 56–69 and 70+ years of age groups were pooled